エリスロポエチン製剤の世界市場規模調査・予測：タイプ別、製品別、用途別、地域別分析、2023年～2030年

世界のエリスロポエチン製剤市場は2022年に約68億7,000万米ドルと評価され、予測期間2023年～2030年には1.5%以上の健全な成長率で成長すると予測されています。

ヘマトポエチンとしても知られるエリスロポエチン（EPO）は、骨髄での赤血球産生を刺激する糖タンパク質ホルモンであり、赤血球造血として知られるプロセスです。当初は末期腎不全（ESRD）や透析などの関連治療から生じる貧血状態に対処するために開発されたが、EPO製剤はその用途を拡大してきました。簡略化後新薬承認申請（ANDA）の成功を受けて、EPO製剤は化学療法による貧血の管理にますます認可されるようになっています。市場成長の原動力となっているのは、慢性疾患の罹患率の上昇やCKD患者数の増加といった主な要因です。

この成長は、がん、末期腎疾患、HIV、神経疾患などの慢性疾患の罹患率の上昇に起因しています。Statistaによると、イタリアで少なくとも2つの慢性疾患を経験している個人の有病率は、2010年から2022年の間に変化し、全体的に上昇傾向を示しました。2018年にはピークが観測され、1,290万人以上が少なくとも2つの慢性疾患に罹患しました。2022年には、約1,260万人のイタリア人が少なくとも2つの慢性疾患と闘っています。さらに、2050年には、この数は約1億7,100万人に急増すると予測されています。米国における慢性疾患の有病率は、1995年以降、徐々に上昇しています。このデータは、米国における1995年から2020年までの慢性疾患患者数と、2025年、2050年の予測です。しかし、代替薬の発売とEPO副作用の需要増が、2023年～2030年の予測期間を通じて市場の成長を阻害しています。

世界のエリスロポエチン製剤市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は2022年に収益シェアでエリスロポエチン製剤市場全体を支配しました。この地域市場は、エリスロポエチン製剤の市場開拓と使用に積極的に取り組んでいる現地組織から大きな恩恵を受けると予想されます。これとともに、アジア太平洋地域は予測期間中に最も速い成長が見込まれています。この地域の成長は、市場における主要企業の存在と、貧血患者を治療するための新しいエリスロポエチン製剤を開発・商業化するための戦略的イニシアティブに起因しています。

本調査の目的は、近年における様々なセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面を取り入れるよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 世界のエリスロポエチン製剤市場の定義と範囲

• 調査目的
• 市場の定義と範囲
  • 産業の発展
  • 調査範囲
• 調査対象年
• 通貨換算レート

第3章 世界のエリスロポエチン製剤市場力学

• エリスロポエチン製剤市場の影響分析（2020年～2030年）
  • 市場促進要因
    • 慢性疾患の増加
    • CKD患者数の増加
  • 市場の課題
    • 代替薬の発売
    • EPOに対する需要の増加副作用
  • 市場機会
    • エリスロポエチン製剤バイオシミラーの製品化動向の上昇
    • EPO治療薬の利点に関する認知度の向上

第4章 世界のエリスロポエチン製剤市場：産業分析

• ポーターのファイブフォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターのファイブフォース影響分析
• PEST分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 環境
  • 法律
• 主な投資機会
• 主要成功戦略
• COVID-19影響分析
• 破壊的動向
• 業界専門家の視点
• アナリストの結論・提言

第5章 世界のエリスロポエチン製剤市場：タイプ別

• 市場スナップショット
• 世界のエリスロポエチン製剤市場：タイプ別、実績 - ポテンシャル分析
• 世界のエリスロポエチン製剤市場：タイプ別、推定・予測（2020年～2030年）
• 世界のエリスロポエチン製剤市場：サブセグメント分析
  • 生物製剤
  • バイオシミラー

第6章 世界のエリスロポエチン製剤市場：製品別

• 市場スナップショット
• 世界のエリスロポエチン製剤市場：製品別、実績 - ポテンシャル分析
• 世界のエリスロポエチン製剤市場：製品別、推定・予測（2020年～2030年）
• 世界のエリスロポエチン製剤市場：サブセグメント分析
  • エリスロポエチン
  • ダルベポエチンアルファ

第7章 世界のエリスロポエチン製剤市場：用途別

• 市場スナップショット
• 世界のエリスロポエチン製剤市場：用途別、実績 - ポテンシャル分析
• 世界のエリスロポエチン製剤市場：用途別、推定・予測（2020年～2030年）
• 世界のエリスロポエチン製剤市場：サブセグメント分析
  • がん
  • 腎疾患
  • 神経
  • その他

第8章 世界のエリスロポエチン製剤市場：地域別分析

• 主要国
• 主な新興国
• 世界のエリスロポエチン製剤市場：地域別の市場スナップショット
• 北米
  • 米国
    • タイプ別の推定・予測（2020年～2030年）
    • 製品別の推定・予測（2020年～2030年）
    • 用途別の推定・予測（2020年～2030年）
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • メキシコ
• 中東・アフリカ
  • サウジアラビア
  • 南アフリカ
  • その他中東・アフリカ

第9章 競合情報

• 主要企業のSWOT分析
• 主要市場戦略
• 企業プロファイル
  • Teva Pharmaceutical Industries Ltd.
    • 主要情報
    • 概要
    • 財務（データの入手可能性によります）
    • 製品概要
    • 最近の動向
  • Johnson & Johnson Services, Inc.
  • Intas Pharmaceuticals Ltd.
  • Novartis AG
  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • LG Chem
  • Biocon
  • Sun Pharmaceutical Industries Ltd
  • Dr. Reddy's Laboratories Ltd

第10章 調査プロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • 検証
  • 出版
• 調査属性
• 調査前提条件

LIST OF TABLES

• TABLE 1. Global Erythropoietin Drugs Market, report scope
• TABLE 2. Global Erythropoietin Drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
• TABLE 3. Global Erythropoietin Drugs Market estimates & forecasts by Type 2020-2030 (USD Billion)
• TABLE 4. Global Erythropoietin Drugs Market estimates & forecasts by Product 2020-2030 (USD Billion)
• TABLE 5. Global Erythropoietin Drugs Market estimates & forecasts by Application 2020-2030 (USD Billion)
• TABLE 6. Global Erythropoietin Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 7. Global Erythropoietin Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 8. Global Erythropoietin Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 9. Global Erythropoietin Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 10. Global Erythropoietin Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 11. Global Erythropoietin Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 12. Global Erythropoietin Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 13. Global Erythropoietin Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 14. Global Erythropoietin Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 15. Global Erythropoietin Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 16. U.S. Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 17. U.S. Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 18. U.S. Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 19. Canada Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 20. Canada Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 21. Canada Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 22. UK Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 23. UK Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 24. UK Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 25. Germany Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 26. Germany Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 27. Germany Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 28. France Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 29. France Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 30. France Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 31. Italy Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 32. Italy Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 33. Italy Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 34. Spain Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 35. Spain Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 36. Spain Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 37. RoE Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 38. RoE Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 39. RoE Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 40. China Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 41. China Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 42. China Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 43. India Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 44. India Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 45. India Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 46. Japan Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 47. Japan Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 48. Japan Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 49. South Korea Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 50. South Korea Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 51. South Korea Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 52. Australia Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 53. Australia Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 54. Australia Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 55. RoAPAC Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 56. RoAPAC Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 57. RoAPAC Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 58. Brazil Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 59. Brazil Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 60. Brazil Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 61. Mexico Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 62. Mexico Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 63. Mexico Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 64. RoLA Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 65. RoLA Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 66. RoLA Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 67. Saudi Arabia Erythropoietin Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 68. South Africa Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 69. RoMEA Erythropoietin Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 70. List of secondary sources, used in the study of global Erythropoietin Drugs Market
• TABLE 71. List of primary sources, used in the study of global Erythropoietin Drugs Market
• TABLE 72. Years considered for the study
• TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

• FIG 1. Global Erythropoietin Drugs Market, research methodology
• FIG 2. Global Erythropoietin Drugs Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Erythropoietin Drugs Market, key trends 2022
• FIG 5. Global Erythropoietin Drugs Market, growth prospects 2023-2030
• FIG 6. Global Erythropoietin Drugs Market, porters 5 force model
• FIG 7. Global Erythropoietin Drugs Market, pest analysis
• FIG 8. Global Erythropoietin Drugs Market, value chain analysis
• FIG 9. Global Erythropoietin Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 10. Global Erythropoietin Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 11. Global Erythropoietin Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 12. Global Erythropoietin Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 13. Global Erythropoietin Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 14. Global Erythropoietin Drugs Market, regional snapshot 2020 & 2030
• FIG 15. North America Erythropoietin Drugs Market 2020 & 2030 (USD Billion)
• FIG 16. Europe Erythropoietin Drugs Market 2020 & 2030 (USD Billion)
• FIG 17. Asia pacific Erythropoietin Drugs Market 2020 & 2030 (USD Billion)
• FIG 18. Latin America Erythropoietin Drugs Market 2020 & 2030 (USD Billion)
• FIG 19. Middle East & Africa Erythropoietin Drugs Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Global Erythropoietin Drugs Market is valued at approximately USD 6.87 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 1.5% during the forecast period 2023-2030. Erythropoietin (EPO), also known as hematopoietin, is a glycoprotein hormone that stimulates the production of red blood cells in the bone marrow, a process known as erythropoiesis. Initially developed to address anemic conditions arising from End-Stage Renal Disease (ESRD) and related treatments such as dialysis, EPO drugs have expanded their applications. Following successful Post-abbreviated New Drug Application (ANDA) approvals, EPO drugs have been increasingly sanctioned for managing chemotherapy-induced anemia. The market growth is driven by key factors such as the rising incidence of chronic diseases and the rising number of CKD cases.

The growth can be attributed to the rising incidence of chronic diseases such as cancer, end-stage renal diseases, HIV, and neurological diseases. As per Statista, the prevalence of individuals experiencing at least two chronic diseases in Italy varied between 2010 and 2022, exhibiting an overall upward trend. In 2018, the peak was observed, with over 12.9 million people affected by at least two chronic diseases. By 2022, approximately 12.6 million Italians were grappling with at least two chronic diseases.. Furthermore, By the year 2050, it is anticipated that this number will surge to approximately 171 million. The prevalence of individuals with chronic conditions in the United States has been on a gradual rise since 1995. This data depicts the count of individuals with chronic medical conditions in the United States spanning from 1995 to 2020, along with projections for 2025 and 2050. However, the launch of alternative drugs and increased demand for EPO Side effects stifle market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Erythropoietin Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the overall erythropoietin drugs market in terms of the revenue share of XX% in 2022. The regional market is anticipated to significantly benefit from local organizations that are actively engaged in advancing the development and use of erythropoietin drugs. Along with this, Asia Pacific is expected to witness fastest growth with CAGR XX% over the forecast period. The growth of the region is attributed to the presence of key players in the market and strategic initiatives undertaken by them to develop and commercialize new erythropoietin drug products to treat anemia patients.

Major market player included in this report are:

• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.
• Intas Pharmaceuticals Ltd.
• Novartis AG
• Amgen, Inc.
• F. Hoffmann-La Roche Ltd.
• LG Chem
• Biocon
• Sun Pharmaceutical Industries Ltd
• Dr. Reddy's Laboratories Ltd

Recent Developments in the Market:

• In November 2022, Dong-A ST forged a strategic partnership with Polifarma regarding the DA-3880 NESP biosimilar. This collaboration granted Polifarma the right to commercialize and advance the development of DA-3880 in the markets of Brazil, Mexico, and Turkey.
• In September 2021, Wanbang Biopharma obtained approval from the National Medical Products Administration (NMPA) for Yi Bao (Human Erythropoietin Injection). This approval signifies its intended use in addressing chemotherapy-related anemia in individuals with non-myeloid malignancies.

Global Erythropoietin Drugs Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Product, Application, Type, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

• Erythropoietin
• Darbepoetin-alfa

By Type:

• Biologics
• Biosimilars

By Application:

• Cancer
• Renal Diseases
• Neurology
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Erythropoietin Drugs Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Erythropoietin Drugs Market, by Type, 2020-2030 (USD Billion)
  • 1.2.3. Erythropoietin Drugs Market, by Product, 2020-2030 (USD Billion)
  • 1.2.4. Erythropoietin Drugs Market, by Application, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Erythropoietin Drugs Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Erythropoietin Drugs Market Dynamics

• 3.1. Erythropoietin Drugs Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising incidence of chronic diseases
    • 3.1.1.2. Rising number of CKD cases
  • 3.1.2. Market Challenges
    • 3.1.2.1. Launch of alternative drugs
    • 3.1.2.2. Increased demand for EPO Side effects
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Rise in trends of commercialization for erythropoietin biosimilars
    • 3.1.3.2. Increase in level of awareness regarding benefits of EPO therapeutics

Chapter 4. Global Erythropoietin Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Erythropoietin Drugs Market, by Type

• 5.1. Market Snapshot
• 5.2. Global Erythropoietin Drugs Market by Type, Performance - Potential Analysis
• 5.3. Global Erythropoietin Drugs Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
• 5.4. Erythropoietin Drugs Market, Sub Segment Analysis
  • 5.4.1. Biologics
  • 5.4.2. Biosimilars

Chapter 6. Global Erythropoietin Drugs Market, by Product

• 6.1. Market Snapshot
• 6.2. Global Erythropoietin Drugs Market by Product, Performance - Potential Analysis
• 6.3. Global Erythropoietin Drugs Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
• 6.4. Erythropoietin Drugs Market, Sub Segment Analysis
  • 6.4.1. Erythropoietin
  • 6.4.2. Darbepoetin-alfa

Chapter 7. Global Erythropoietin Drugs Market, by Application

• 7.1. Market Snapshot
• 7.2. Global Erythropoietin Drugs Market by Application, Performance - Potential Analysis
• 7.3. Global Erythropoietin Drugs Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
• 7.4. Erythropoietin Drugs Market, Sub Segment Analysis
  • 7.4.1. Cancer
  • 7.4.2. Renal Diseases
  • 7.4.3. Neurology
  • 7.4.4. Others

Chapter 8. Global Erythropoietin Drugs Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Erythropoietin Drugs Market, Regional Market Snapshot
• 8.4. North America Erythropoietin Drugs Market
  • 8.4.1. U.S. Erythropoietin Drugs Market
    • 8.4.1.1. Type breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Product breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. Application breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Erythropoietin Drugs Market
• 8.5. Europe Erythropoietin Drugs Market Snapshot
  • 8.5.1. U.K. Erythropoietin Drugs Market
  • 8.5.2. Germany Erythropoietin Drugs Market
  • 8.5.3. France Erythropoietin Drugs Market
  • 8.5.4. Spain Erythropoietin Drugs Market
  • 8.5.5. Italy Erythropoietin Drugs Market
  • 8.5.6. Rest of Europe Erythropoietin Drugs Market
• 8.6. Asia-Pacific Erythropoietin Drugs Market Snapshot
  • 8.6.1. China Erythropoietin Drugs Market
  • 8.6.2. India Erythropoietin Drugs Market
  • 8.6.3. Japan Erythropoietin Drugs Market
  • 8.6.4. Australia Erythropoietin Drugs Market
  • 8.6.5. South Korea Erythropoietin Drugs Market
  • 8.6.6. Rest of Asia Pacific Erythropoietin Drugs Market
• 8.7. Latin America Erythropoietin Drugs Market Snapshot
  • 8.7.1. Brazil Erythropoietin Drugs Market
  • 8.7.2. Mexico Erythropoietin Drugs Market
• 8.8. Middle East & Africa Erythropoietin Drugs Market
  • 8.8.1. Saudi Arabia Erythropoietin Drugs Market
  • 8.8.2. South Africa Erythropoietin Drugs Market
  • 8.8.3. Rest of Middle East & Africa Erythropoietin Drugs Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Teva Pharmaceutical Industries Ltd.
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. Johnson & Johnson Services, Inc.
  • 9.3.3. Intas Pharmaceuticals Ltd.
  • 9.3.4. Novartis AG
  • 9.3.5. Amgen, Inc.
  • 9.3.6. F. Hoffmann-La Roche Ltd.
  • 9.3.7. LG Chem
  • 9.3.8. Biocon
  • 9.3.9. Sun Pharmaceutical Industries Ltd
  • 9.3.10. Dr. Reddy's Laboratories Ltd

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption